ALV vs TSLA

Autoliv (ALV) shows mixed financial health with a weak Piotroski F-Score of 4/9, indicating borderline stability, and no available Altman Z-Score to assess distress risk. The stock appears reasonably valued with a P/E of 13.03 below sector average, strong ROE of 31.01%, and solid earnings growth of 31% YoY, but faces concerns around liquidity (Current Ratio: 0.95) and technical weakness (Technical Trend: 10/100). Dividend strength is moderate at 50/100 with a sustainable 2.48% yield, while analyst consensus leans positive with a $138.72 target price. However, insider sentiment is lukewarm and recent price performance shows decelerating momentum despite solid long-term returns.

Tesla's deterministic health is marginally stable with a Piotroski F-Score of 4/9, but the valuation is fundamentally decoupled from financial performance. The stock trades at a massive premium to its Graham Number ($23.07) and Intrinsic Value ($7.56), while exhibiting negative revenue growth (-3.10%) and a severe collapse in earnings growth (-60.60%). With zero earnings beats in the last four quarters and bearish insider activity, the current price is supported by sentiment rather than data.